Results from the phase 3 PARADIGM trial - report from ASCO2022

from Medical Digest & Congress Report · host Medical Congress News

Professor Takayuki Yoshino presented at the recent ASCO 2022 new data about the PARADIGM trial. He summerized us the main findings. (Panitumumab plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 as first‐line treatment in patients with RAS wild‐type metastatic colorectal cancer) Video: https://congressreport.eu/scientific-contents/interview:results-phase-3-paradigm-trial

Episode metadata supplied by the publisher feed · Published Jun 16, 2022

Embed this episode

Attribution link and audio player

NOW PLAYING

Results from the phase 3 PARADIGM trial - report from ASCO2022

0:00 5:09

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Medical Digest & Congress Report?

This episode is 5 minutes long.

When was this Medical Digest & Congress Report episode published?

This episode was published on June 16, 2022.

Can I download this Medical Digest & Congress Report episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!